CRDF vs. CMPX, OPT, SVRA, KALV, BCYC, CTMX, RGNX, MNPR, PRTA, and ETON
Should you be buying Cardiff Oncology stock or one of its competitors? The main competitors of Cardiff Oncology include Compass Therapeutics (CMPX), Opthea (OPT), Savara (SVRA), KalVista Pharmaceuticals (KALV), Bicycle Therapeutics (BCYC), CytomX Therapeutics (CTMX), REGENXBIO (RGNX), Monopar Therapeutics (MNPR), Prothena (PRTA), and Eton Pharmaceuticals (ETON). These companies are all part of the "pharmaceutical products" industry.
Cardiff Oncology vs. Its Competitors
Cardiff Oncology (NASDAQ:CRDF) and Compass Therapeutics (NASDAQ:CMPX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, profitability, dividends, media sentiment and institutional ownership.
Compass Therapeutics has a net margin of 0.00% compared to Cardiff Oncology's net margin of -9,344.14%. Compass Therapeutics' return on equity of -53.11% beat Cardiff Oncology's return on equity.
Cardiff Oncology currently has a consensus target price of $10.63, indicating a potential upside of 385.16%. Compass Therapeutics has a consensus target price of $13.10, indicating a potential upside of 207.51%. Given Cardiff Oncology's higher possible upside, equities research analysts clearly believe Cardiff Oncology is more favorable than Compass Therapeutics.
In the previous week, Compass Therapeutics had 3 more articles in the media than Cardiff Oncology. MarketBeat recorded 4 mentions for Compass Therapeutics and 1 mentions for Cardiff Oncology. Cardiff Oncology's average media sentiment score of 1.54 beat Compass Therapeutics' score of 0.20 indicating that Cardiff Oncology is being referred to more favorably in the media.
Cardiff Oncology has a beta of 1.62, indicating that its share price is 62% more volatile than the S&P 500. Comparatively, Compass Therapeutics has a beta of 1.48, indicating that its share price is 48% more volatile than the S&P 500.
Cardiff Oncology has higher earnings, but lower revenue than Compass Therapeutics. Compass Therapeutics is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks.
16.3% of Cardiff Oncology shares are owned by institutional investors. Comparatively, 68.4% of Compass Therapeutics shares are owned by institutional investors. 7.7% of Cardiff Oncology shares are owned by company insiders. Comparatively, 29.8% of Compass Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Summary
Compass Therapeutics beats Cardiff Oncology on 12 of the 17 factors compared between the two stocks.
Get Cardiff Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRDF and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CRDF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cardiff Oncology Competitors List
Related Companies and Tools
This page (NASDAQ:CRDF) was last updated on 10/19/2025 by MarketBeat.com Staff
